中国癌症杂志 ›› 2013, Vol. 23 ›› Issue (6): 452-456.doi: 10.3969/j.issn.1007-3969.2013.06.009

• 论著 • 上一篇    下一篇

A(N2)期非小细胞肺癌术后放疗疗效分析

刘翼1,阿迪力1,陆艳荣2,张国庆1,庞作良1   

  1. 1.新疆医科大学附属肿瘤医院胸外科,新疆 乌鲁木齐 830011

    2.新疆医科大学附属肿瘤医院胸部放疗科,新疆 乌鲁木齐 830011

  • 出版日期:2013-06-25 发布日期:2014-11-13
  • 通信作者: 张国庆 E-mail:zgqprofessor@163.com

Analyze the curative effect of adjuwant radiotherapy in stage ⅢA(N2) non-small cell lung cancer

LIU Yi, A Di-li , LU Yan-rong, ZHANG Guo-qing, PANG Zuo-liang   

  1. 1.Department of Thoracic Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi Xinjiang 830011, China; 2. Department of Radiotherapy, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi Xinjiang 830011, China
  • Published:2013-06-25 Online:2014-11-13
  • Contact: ZHANG Guo-qing E-mail: zgqprofessor@163.com

摘要:

背景与目的:术后放射治疗(postoperative radiotherapyPORT)在完全性切除的ⅢA(N2)期非小细胞肺癌(non-small cell lung cancerNSCLC)治疗中的临床价值存在争议。本研究分析PORT在完全性切除的ⅢA(N2)NSCLC的疗效。方法:回顾性分析20021月—20071126例在我院接受手术治疗的ⅢA(N2)NSCLC患者的临床资料。根据是否行术后放疗分为术后化疗组(n=56)和术后放化疗组(n=70),分析ⅢA(N2)NSCLC生存期的影响因素。统计分析采用Kaplan-Meier法计算生存率,采用Log-rank比较各组生存的差异。结果:全组患者中位生存期25.0个月,135年生存率分别为84.4%32.5%16.4%。术后化疗组135年生存率分别为81.2%28.5%13.5%,中位生存期为22.4个月,术后化疗联合放疗组135年生存率分别为88.5%39.9%20.0%,中位生存期32.8个月,差异有统计学意义(P=0.033)。术后化疗组出现局部复发的中位时间为9.6个月,术后化疗联合放疗组出现局部复发的中位时间为17.0个月,差异有统计学意义(P=0.001)。单因素分析发现,多站淋巴结转移(P=0.001)PORT(P=0.033)影响ⅢA(N2)NSCLC的生存率。结论:术后辅助放疗可提高pN2NSCLC的生存率和降低局部复发。

关键词: 非小细胞肺癌, 生存期, 术后放疗

Abstract:

Background and purpose: Postoperative radiotherapy (PORT) in completely resectable stage A(N2) non-small cell lung cancer (NSCLC) is still controversial. The purpose of this study was to analyze the efficiency of PORT in completely resectable stage A(N2) NSCLC. Methods: The clinical data of 126 patients with stage A(N2) NSCLC who was treated with radical surgery from Jan. 2002 to Jan. 2007 were retrospctively analyzed. There were 126 patients for analysis; 70 patients received the postoperative chemotherapy alone (non-PORT), 56 patients received postoperative chemotherapy with radiotherapy. The 126 patients were analyzed the influencing factors of the overall survival (OS). Kaplan-Meier method was used to calculate the OS, and Log-rank was used to compare the difference of OS between the two groups. Results: The median survival time was 25.0 months in all the groups of patients. The 1-, 3-, 5-year survival rates were 84.4%, 32.5%, 16.4%. The 1-, 3-, and 5-year survival rates were 81.2%, 28.5%, 13.5% in non-PORT group, and 88.5%, 39.9%, 20.0% in PORT group. The median survival time was 22.4 months and 32.8 months, the difference was statistically significant (P=0.033). The median time of stage A(N2) NSCLC with locoregional recurrence was 9.6 months in non-PORT group and 17.0 months in PORT group, the difference was statistically significant (P=0.001). Univariate analysis showed that the number of lymph node metastasis station (P=0.001) and PORT (P=0.033) correlated with OS. Conclusion: PORT could improve the survival rate and reduce the locoregional recurrence of stage A(N2) NSCLC.

Key words: Non-small cell lung cancer, Survival rate, Postoperative radiothera